Table 5:
fisrt line therapy in adults
| low C3 | low C3 | Normal C3 | Normal C3 | P value | |
|---|---|---|---|---|---|
| normal sC5b-9 | high sC5B-9 | normal sC5b-9 | high sC5b-9 | ||
| First line therapy | |||||
| No treatment | 6/15 (40%) | 8/32 (25%) | 9/20 (45%) | 5/12 (42%) | 0.44 |
| Immunosuppresive treatment n (%) | 9/15 (40%) | 24/32 (75%) | 11/20 (55%) | 7/12 (58%) | 0.44 |
| Corticosteroids alone n (%) | 1/9 (11%) | 6/23 (26%) | 3/11 (27%) | 4/7 (57%) | 0.23 |
| Rituximab-based regimen n (%) | 1/9 (11%) | 3/23 (13%) | 0/11 (0%) | 2/7 (29%) | 0.34 |
| Cyclophosphamid-based regimen | 1/9 (11%) | 0/23 (0%) | 1/11 9%) | 0/7 (0%) | 0.36 |
| Mycofenolate mofetil-based regimen n (%) | 3/9 (33%) | 9/23 (39%) | 6/11 (55%) | 0/7 (0%) | 0.12 |
| Monoclonal anti-C5 n (%) | 3/9 (33%) | 5/23 (22%) | 1/10 (10%) | 1/7 (14%) | 0.61 |
| Second line therapy | 1/9 (11%) | 4/23 (17%) | 2/10 (20%) | 0/7 (0%) | 0.63 |
| Monoclonal anti-C5 n (%) | 1/1 | 2/4 | 0/2 | - | |
| Others n (%) | 0 | 2/4 | 2/2 | - |